The management of anticoagulant therapy (OAT) in patients with factor VII (FVII) deficiency is a very challenging clinical issue, as warfarin further reduces FVII levels, thus potentially increasing bleeding risk. On the other hand, the International Normalized Ratio test is misleading in such patients, as they do not reflect the actual level of global inhibition of the coagulation system. We report here three cases of patients with a moderate FVII deficiency and receiving direct oral anticoagulants (DOAC) for prevention of cardioembolism in atrial fibrillation. Of note, two of them experienced a treatment failure while on warfarin, while DOAC treatment was not associated with thrombotic or hemorrhagic adverse events. DOAC are very attractive for the management of OAT in FVII deficient patients, because they do not require monitoring by tests affected by the inherited defect, and their mechanism of action is FVII-independent.

Direct oral anticoagulants for atrial fibrillation in patients with congenital factor VII deficiency / Arletti, L.; Coluccio, V.; Romagnoli, E.; Luppi, M.; Marietta, M.. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - 103:1(2019), pp. 67-69. [10.1111/ejh.13246]

Direct oral anticoagulants for atrial fibrillation in patients with congenital factor VII deficiency

Arletti L.;Coluccio V.;Romagnoli E.;Luppi M.;Marietta M.
2019-01-01

Abstract

The management of anticoagulant therapy (OAT) in patients with factor VII (FVII) deficiency is a very challenging clinical issue, as warfarin further reduces FVII levels, thus potentially increasing bleeding risk. On the other hand, the International Normalized Ratio test is misleading in such patients, as they do not reflect the actual level of global inhibition of the coagulation system. We report here three cases of patients with a moderate FVII deficiency and receiving direct oral anticoagulants (DOAC) for prevention of cardioembolism in atrial fibrillation. Of note, two of them experienced a treatment failure while on warfarin, while DOAC treatment was not associated with thrombotic or hemorrhagic adverse events. DOAC are very attractive for the management of OAT in FVII deficient patients, because they do not require monitoring by tests affected by the inherited defect, and their mechanism of action is FVII-independent.
2019
103
1
67
69
Direct oral anticoagulants for atrial fibrillation in patients with congenital factor VII deficiency / Arletti, L.; Coluccio, V.; Romagnoli, E.; Luppi, M.; Marietta, M.. - In: EUROPEAN JOURNAL OF HAEMATOLOGY. - ISSN 0902-4441. - 103:1(2019), pp. 67-69. [10.1111/ejh.13246]
Arletti, L.; Coluccio, V.; Romagnoli, E.; Luppi, M.; Marietta, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1222773
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 3
  • ???jsp.display-item.citation.isi??? 3
social impact